Lumenis OptiLIFT Receives Health Canada Approval for Evaporative Dry Eye Use
Wednesday, May 6 2026 | 11 h 39 min | News
Lumenis has announced that Health Canada has authorized OptiLIFT™ and its proprietary Dynamic Muscle Stimulation (DMSt) technology for reducing signs and symptoms of evaporative dry eye disease, while also improving lower lid laxity and blinking mechanism.
According to the company, the approval makes Lumenis the first to offer a muscle stimulation device in Canada cleared for ophthalmic use. OptiLIFT joins the company’s growing dry eye portfolio, which also includes OptiLIGHT, its intense pulsed light technology authorized in Canada for dry eye management.
OptiLIFT is intended to address an area of dry eye care that has traditionally had limited treatment options. Lower lid laxity and incomplete blinking are associated with tear film instability and ocular surface symptoms and may become more common with age as periocular muscle tone decreases.
The device uses Dynamic Muscle Stimulation to strengthen the periorbital muscle area, with the goal of improving blink quality and lower lid support through a non-surgical approach. OptiLIFT is also indicated for non-invasive skin tightening and wrinkle treatment, allowing eye care professionals to incorporate aesthetic services through the same platform.
Lumenis cited a study published in Clinical Ophthalmology examining the use of its DMSt technology in patients with lower lid laxity and dry eye disease. According to the company, the study reported improvements in lower lid laxity, blinking quality, tear break-up time, ocular surface symptoms, and eyelid appearance over the course of treatment.
“Dry eye disease is inherently multifactorial, and eyelid dynamics—particularly lower lid laxity and blink dysfunction—are frequently underrecognized contributors to tear film instability and ocular surface disease,” said Laura M. Periman, MD, Director of Dry Eye Services and Clinical Research at Periman Eye Institute in Seattle. She said supporting periocular muscle function may help improve tear distribution and ocular surface health in some patients seeking non-surgical options.
In a statement, Itay Mayer, Chief Commercial Officer at Lumenis, said the company sees OptiLIFT as addressing a gap in care for patients affected by lower eyelid laxity and impaired blinking.
Click HERE for the press release.
Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!
